Impax Laboratories (IPXL) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Impax Reports First Quarter 2016 Financial Results
May 10, 2016 6:40 AM EDTHAYWARD, Calif., May 10, 2016 /PRNewswire/ --Â Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today reported first quarter 2016 financial results for the quarter ended March 31, 2016.
Logo - http://photos.prnewswire.com/prnh/20150310/180590LOGO
First quarter 2016 total revenues of $225.5 million compared to $143.1 million in the prior year period. Adjusted diluted earnings per share (Adjusted EPS) for the first quarter 2016 of $0.43 compared to Adjusted... More